BIOGEN INC. Excess Tax Benefit from Share-based Compensation, Operating Activities
BIOGEN INC. (BIIB) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $54.74 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2013-02-05
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2011-12-31 was $7.04M, a 2.76% increase year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2011-09-30 was $5.72M, a 733.53% increase year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2011-06-30 was $27.77M, a 2177.85% increase year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2011-03-31 was $10.06M, a 129.73% increase year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for fiscal 2012 was $54.74M, a 8.21% increase from fiscal 2011.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for fiscal 2011 was $50.59M, a 285.09% increase from fiscal 2010.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for fiscal 2010 was $13.14M, a 282.31% increase from fiscal 2009.
- BIOGEN INC. excess tax benefit from share-based compensation, operating activities for fiscal 2009 was $3.44M, a 87.72% decline from fiscal 2008.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2012-12-31 | $54.74M 10-K · filed 2013-02-05 | |||||||
| 2011-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $12.76M derived: sum of 2 quarters · filed 2013-02-05 | $40.53M derived: sum of 3 quarters · filed 2013-02-05 | $50.59M 10-K · filed 2013-02-05 | ||||
| 2011-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $33.48M derived: sum of 2 quarters · filed 2011-10-28 | $43.55M 10-Q · filed 2011-10-28 | $50.40M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | $27.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $37.83M 10-Q · filed 2011-07-26 | $44.68M derived: sum of 3 quarters · filed 2013-02-05 | $45.37M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $10.06M 10-Q · filed 2011-04-21 | $16.91M derived: sum of 2 quarters · filed 2013-02-05 | $17.60M derived: sum of 3 quarters · filed 2013-02-05 | $18.82M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | $6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $7.54M derived: sum of 2 quarters · filed 2013-02-05 | $8.76M derived: sum of 3 quarters · filed 2013-02-05 | $13.14M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $1.91M derived: sum of 2 quarters · filed 2011-10-28 | $6.28M 10-Q · filed 2011-10-28 | $6.53M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $5.60M 10-Q · filed 2011-07-26 | $5.84M derived: sum of 3 quarters · filed 2012-02-03 | $6.23M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $4.38M 10-Q · filed 2011-04-21 | -$4.38M 10-Q · filed 2010-04-20 | $4.62M derived: sum of 2 quarters · filed 2012-02-03 | $5.01M derived: sum of 3 quarters · filed 2012-02-03 | $10.10M derived: sum of 4 quarters · filed 2012-02-03 | |||
| 2009-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $636.00K derived: sum of 2 quarters · filed 2012-02-03 | $5.72M derived: sum of 3 quarters · filed 2012-02-03 | $3.44M 10-K · filed 2012-02-03 | -$3.44M 10-K · filed 2010-02-09 | |||
| 2009-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $5.48M derived: sum of 2 quarters · filed 2010-10-26 | $3.19M 10-Q · filed 2010-10-26 | -$3.19M 10-Q · filed 2009-10-21 | $58.61M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-06-30 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $2.80M 10-Q · filed 2010-07-20 | -$2.80M 10-Q · filed 2009-07-17 | $58.21M derived: sum of 3 quarters · filed 2011-02-04 | $49.24M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-03-31 | -$2.28M 10-Q · filed 2010-04-20 | $53.13M derived: sum of 2 quarters · filed 2011-02-04 | $44.16M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | $55.41M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $46.44M derived: sum of 2 quarters · filed 2011-02-04 | $27.99M 10-K · filed 2011-02-04 | -$27.99M 10-K · filed 2010-02-09 | ||||
| 2008-09-30 | -$8.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | -$27.42M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | -$18.45M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | -$69.67M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |